Table 1.
Demographic and clinical data concerning patient gender, age, comorbidities, concomitant cancer therapies, stage, and localization of medication-related osteonecrosis of the jaw (MRONJ) (n = 35).
| Demographic and Clinical Data | Number of Patients (%) |
|---|---|
| Gender | |
| -Male | 11 (31.4%) |
| -Female | 24 (68.6%) * |
| Age, years | Years |
| Range | 51–93 |
| Mean, SD | 73.46 ± 9.29 |
| Concomitant cancer therapies | |
| -Steroids | 4 (11.4%) |
| -Chemotherapy | 6 (17.1%) |
| -Steroids and Chemotherapy | 4 (11.4%) |
| -No steroids, No Chemotherapy | 21 (60%) |
| Primary disease requiring anti-resorptive drugs | |
| -Breast cancer | 10 (28.6%) |
| -Prostate cancer | 4 (11.4%) |
| -Multiple myeloma | 7 (20%) |
| -Osteoporosis | 14 (40%) |
| Type of drug associated with MRONJ | |
| Zolendronate | 17 (48.5%) * |
| Alendronate | 9 (25.7%) |
| Denosumab | 2 (5.7%) |
| Alendronate + Denosumab | 2 (5.7%) |
| Alendronate + Risendronate | 1(2.9%) |
| Alendronate + Zolendronate | 1(2.9%) |
| Alendronate + Ibandronate | 1(2.9%) |
| Ibandronate + Clodronate | 1 (2.9%) |
| Zolendronate + Denosumab | 1 (2.9%) |
| Stage of MRONJ | |
| -Stage I | 6 (17.1%) |
| -Stage II | 28 (80%) |
| -Stage III | 1 (2.9%) * |
| MRONJ localization | |
| Maxilla | 12 (34.2%) |
| Mandible | 24 (68.5%) * ψ |
* χ2 test, significance: p ≤ 0.05. ψ One patient had both mandibular and maxillary lesions.